Catalent Inks Deal to Manufacture Mantra’s Single-Serve Oral Gel Portfolio
Event summary
- Catalent will provide formulation development, commercial manufacturing, and packaging services for Mantra’s oral gel products at its St. Petersburg, Florida facility.
- Mantra’s products target occasional sleeplessness, pain relief, and menstrual relief in single-serve, portable pouches.
- The agreement marks Catalent’s first foray into OTC unit-dose gel technology.
- Mantra’s products are free from artificial dyes, flavors, sweeteners, and preservatives.
The big picture
This partnership underscores the increasing demand for convenient, clean-label self-care solutions. Catalent’s manufacturing expertise paired with Mantra’s innovative product format could set a new standard in the OTC market. The deal also highlights the strategic shift toward unit-dose formats in consumer health, reflecting broader industry trends toward personalized and portable wellness products.
What we're watching
- Market Expansion
- How Catalent’s entry into OTC unit-dose gel technology will position it in the growing self-care market.
- Execution Risk
- Whether Catalent can scale production to meet Mantra’s commercialization needs efficiently.
- Consumer Adoption
- The pace at which Mantra’s innovative format gains traction among health-conscious consumers.
Related topics
